Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment ...

Bio-Techne Corporation recently launched the ProximityScope™ assay, an innovative spatial biology solution designed for integration with Leica Biosystems' BOND RX platform, enabling subcellular ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Bio-Techne will report earnings from the most recent quarter on October 31. Wall Street analysts predict earnings per share of $0.435. Track Bio-Techne stock price in real-time ahead here. On October ...

MINNEAPOLIS and TOLOCHENAZ, Switzerland, June 22, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein ...

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual ...

Bio-Techne Corporation TECH is set to release first-quarter fiscal 2026 results on Nov. 5, before the opening bell. The life ...

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Evercore ISI Group on October 7, 2025. The analyst firm set a price target for $72.00 expecting TECH to rise to within 12 months (a ...

A Minnesota life sciences company said it had agreed to buy Wallingford biochemical test maker CyVek for as much as $195 million in cash and incentives. Bio-Techne Corp. said it would pay $60 million ...

More than 600,000 times, researchers have cited Bio-Techne Corp. in academic papers as a manufacturer of tools that helped in their search for new tests and treatments. The company, Minnesota's ...